Details for Investors
Cutia Therapeutics has notified the market and its shareholders of a change in the legal name of its principal share registrar and transfer office in the Cayman Islands. The new entity, Ascentium (Cayman) Limited, replaces Harneys Fiduciary (Cayman) Limited starting from 17 April 2026. This administrative change is part of the company’s ongoing efforts to ensure transparency and compliance with regulatory standards.
Importantly, the address of the registrar and registered office remains unchanged. This means that shareholders and stakeholders will not need to update their records regarding the physical location, and there will be no disruption to normal operations or communications.
The announcement also includes a full list of directors, reflecting a stable and experienced leadership structure:
- Executive Directors: Ms. Zhang Lele (Chief Executive Officer), Mr. Huang Yuqing
- Non-Executive Directors: Dr. Chen Lian Yong, Dr. Xie Qin, Mr. Lu Minfang, Ms. Yang Yunxia
- Independent Non-Executive Directors: Mr. Chung Ming Kit, Mr. Zhang Zhisong, Mr. Ye Xiaoxiang
Potential Impact for Shareholders
This change is primarily administrative and does not involve any operational, strategic, or financial modifications within the company. There are no indications that this change will directly affect share values or the company’s business model. However, such transparency and compliance-related updates are generally viewed positively as they reflect good corporate governance practices.
Shareholders do not need to take any action as a result of this change, but it is advisable to stay updated with any future communications regarding administrative or corporate changes.
Is This News Price Sensitive?
Based on the information provided, this change is not price sensitive and is unlikely to directly impact the share price. It is an administrative update with no effect on the company’s financial position, assets, operations, or investor rights.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult with professional advisors before making investment decisions. The information provided herein is based on company announcements and may be subject to change.
View CUTIA-B Historical chart here
